Biotech Breakthroughs: Dyadic International (NASDAQ: DYAI) Partners with Rabian BV to Combat Rabies

Today, most investors are going to focus on those companies that were in the news cycle for one reason or another on Wednesday. One of the companies that could be worth looking into is the global biotech company Dyadic International (NASDAQ: DYAI), which is involved in deploying its innovative medical protein production platforms to meet the growing worldwide protein bio-production demands. 

On February 21, 2024, the stock peaked for the month, reaching $1.51, marking an 11.85% increase for the day. Subsequently, the stock dipped below the 50-day moving average (DMA). However, yesterday, it found support at the 20 DMA. This suggests that the stock, which is currently undervalued, warrants close attention in the future. 

These proteins are designed to address the demand for cost-effective, accessible, and efficient biopharmaceuticals for both animal and human health needs. On Wednesday, Dyadic International’s Dutch subsidiary, Dyadic Nederland BV, revealed a strategic collaboration with Rabian BV, a Netherlands-based SME founded by vaccine experts and experienced entrepreneurs. This partnership aims to develop scalable, cost-effective, and potent abies prophylactics and vaccines using Dyadic’s CI protein production platform. 

Through their collaboration, the two organizations aim to tackle the worldwide issue of rabies, a highly infectious disease responsible for tens of thousands of deaths annually. Rabian has secured a total of 1.7 million euros from Eurostars for the Avatar project, leveraging its expertise in virology to develop a rabies vaccine. 

Under the project, Rabian will utilize Dyadic’s C1 platform. According to the terms of their agreement, Dyadic will receive an equity share in the project and royalties upon commercialization of the product. Dyadic’s CEO, Mark Emelfarb, also commented on the collaboration, expressing enthusiasm about the prospect of furthering their longstanding relationship with Rabian.


Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States